Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 22, 2022
Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xuezhikang,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Xuezhikang,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 17, 2021
Lead Product(s) : Insulin,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Weight Loss Aid in an Exposed Population
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2018
Lead Product(s) : Orlistat,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Scopolamine,Meclizine Hydrochloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Motion Sickness Medications and Vestibular Time Constant
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2017
Lead Product(s) : Scopolamine,Meclizine Hydrochloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sugammadex Sodium,Rocuronium Bromide,Fentanyl,Propofol,Sevoflurane
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2016
Lead Product(s) : Sugammadex Sodium,Rocuronium Bromide,Fentanyl,Propofol,Sevoflurane
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propofol,Desflurane
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Baxter Healthcare Corporation | Medtronic plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2015
Lead Product(s) : Propofol,Desflurane
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Baxter Healthcare Corporation | Medtronic plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluvastatin Sodium,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2012
Lead Product(s) : Fluvastatin Sodium,Inapplicable
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable